Comparison · NCT00930644-sae
NT,PBO/TED vs TED/TED: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. NT,PBO/TED vs TED/TED: serious adverse events. Trial comparisons, record NCT00930644-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00930644-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.627 | 0.49 | 0.747 | wilson | |
| Risk in group 2 | 0.649 | 0.488 | 0.782 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0212 | -0.212 | 0.179 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.967 | 0.704 | 1.33 | log | |
| Odds ratio, group 1 over group 2 | 0.912 | 0.378 | 2.2 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on NT,PBO/TED than on TED/TED | 47.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | NT,PBO/TED | No treatment or placebo in CL0600-020 trial and teduglutide 0.05 mg/kg/day subcutaneously taken once per day for 24 months in CL0600-021 trial | 32 | 51 | EG000 |
| Group 2 | TED/TED | 0.05 mg/kg/day subcutaneously taken once per day for 6 months CL0600-020 trial and teduglutide 0.05 mg/kg/day subcutaneously taken once per day for 24 months in CL0600-021 trial | 24 | 37 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse event data were collected for each subject from the time informed consent was signed to the end of the study. The most commonly reported treatment emergent adverse events (>= 3% grouped at PT level) are listed.
Source ClinicalTrials.gov
Trial
- Title
- Open-Label Study of Teduglutide for Subjects With PN-Dependent Short Bowel Syndrome (SBS)
- NCT number
- NCT00930644
- Phases
- PHASE3
- Conditions
- Short Bowel Syndrome
- Interventions
- teduglutide
- Lead sponsor
- Shire
- Results first posted
- 2014-12-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00930644?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00930644-sae